The global Meningococcal Vaccines Market stands at US$ 3.4 Billion as of now and is expected to reach US$ 7.7 Billion by the year 2032 at a CAGR of 8.6% between 2022 and 2032.
Vaccines that are into targeting some meningococcus strains like A, B, C, W-135, and Y are being made available. It is a known fact that vaccines enhance immunity levels by 80-100% for 2 years, with some of them needing booster doses. Plus, with spike in travel vaccine and enclosure of National Immunization Programs all over, the meningococcal vaccines market is expected to grow on an unstoppable note in the near future.
The present scenario is such that resistance to antibiotics is rising. This is evident from the fact that various clonal complexes of Neisseria meningitidis like CC11 and CC4821 are exhibiting resistance with respect to antibiotics. This is another factor fostering continued research regarding meningococcal vaccines.
Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1252
At the same time, the fact that there is stringency regarding regulatory guidelines as far as the approval of vaccines is concerned can’t be ignored. Some of the leading bodies involved in the approval of vaccines include EMA (European Medicines Agency) and the US FDA. Plus, these guideless are not in uniformity all over. These factors are likely to hamper the meningococcal vaccine market in the near future.
Apart from polysaccharides and conjugates, subcapsular vaccines are being discussed these days. They combine the advantages offered by both of them. As such, a mixed bag is always good to opt for. Future Market Insights has entailed these facts with future courses of action in its latest market study entitled ‘Meningococcal Vaccines Market’. The immaculate team of analysts and consultants has gone for bottom-up approach in this regard.
Key Takeaways from Meningococcal Vaccines Market
- North America holds the largest market share. This could be attributed to well-established healthcare infrastructure along with rise in awareness campaigns regarding meningococcal vaccines. On these grounds, GlaxoSmithKline, in August 2021, came up with ASK2BSure campaign to encourage parents to check with doctors to get their children vaccinated against meningitis B.
Inquire Before Buying Research Report: https://www.futuremarketinsights.com/ask-question/rep-gb-1252
- Europe stands second on this count and would continue with its winning streak in the upcoming period. As per the European Centre for Disease Prevention and Control, IMD (Invasive Meningococcal Disease) is amongst the leading causes of septicemia and meningitis, with close to 200K cases witnessed every single year. There are European countries planning meningococcal vaccination programs.
- The Asia-Pacific is expected to grow at the fastest rate in the meningococcal vaccines market in the near future. This could be credited to initiatives taken by the governments regarding preventing the further prevalence of meningitis.
Competitive Analysis
- GlaxoSmithKline plc, in August 2020, started with patient dosing in phase III clinical study, wherein it compared 5-in-1 meningitis (MenABCWY) vaccine candidate against Menveo and Bexsero (licensed meningococcal vaccines.
- The EC (European Commission), in November 2020, authorized MenQuadfi to actively vaccinate people aged 12 and above against meningococcal illnesses caused due to Neisseria meningitis serogroups A, C, W, and Y.
- Pfizer Inc., in June 2020, began Phase III clinical trials pertaining to PF-06886992. It’s a pentavalent meningococcal vaccine candidate (MenABCWY).
- Bio-Manguinhos, in May 2021, inked an agreement with Emergex (UK) with the objective of establishing framework for subsequent clinical trials for producing meningococcal vaccine, Covid-19 vaccine, distribution, and marketing within Brazil.
- GlaxoSmithKline, in May 2022, did announce that it would pay nearly US$ 3.3 Bn for acquiring Affinivax for bolstering the vaccines’ pipeline.
- The University of Maryland School of Medicine (UMSOM), in March 2022, started leading research for assessing meningococcal vaccine for young children and infants in Africa.
“With growing occurrences of meningitis all over, the global meningococcal vaccines market is bound to witness an escalation in the near future”, says an analyst from Future Market Insights.
Use promo code ->> FMITODAY to get a flat 20% discount
Key Companies Profiled:
- Pfizer Inc.
- GlaxoSmithKline plc.
- Sanofi SA
- Serum Institute of India
- Walvax Biotechnology Co., Ltd.
- Incepta Pharmaceuticals Limited
- Hualan Biological Engineering Inc.
Key Market Segments Covered in Meningococcal Vaccines Industry Research
By Product:
- Polysaccharide
- Conjugate
By Age Group:
- Infants
- Children
- Adolescents & young Adults
- Adults
By Distribution Channel:
- Pharmacies
- Community Clinics
- Public Health Agencies
- Others (hospital pharmacy, private market, etc.)
Have a Look at Healthcare Domain Related Research Reports:
- https://club.vexanium.com/post/infertility-drugs-market-is-projected-to-reach-us-6-814-68-million-by-2033—63f7405f523cbf279378c37e
- https://www.evernote.com/shard/s727/sh/052586fe-618f-eb23-38b0-9fe010254a65/JVnWpYlfgR0CXfVrSe40Nn4AIv5uutHxfeXsIf0jZ0C7fLscdGezC29w3g
- https://writer.zohopublic.in/writer/published/d98ahdf8710de79e4484d9a3a1d15b1304ed7
About Future Market Insights (FMI)
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
